CURRICULUM VITAE
Fumou Sun PhD
Fumou Sun PhD
Assistant Professor
Department of Medicine
Division of Hematology and Oncology - Medicine
Department of Medicine
Division of Hematology and Oncology - Medicine
OFFICE ADDRESS: |
MCW Business Group |
8701 Watertown Plank Rd |
Milwaukee, WI 53226 |
Phone: 414-955-2117 |
Email: fsun@mcw.edu |
EDUCATION: |
09/2009 - 06/2013 B.S. in Pharmacology, China Pharmaceutical University, Nanjing, China |
09/2014 - 06/2016 M.S. in Biology, China Pharmaceutical University, Nanjing, China |
09/2016 - 06/2019 PhD in Microbial and Biochemical Pharmacy, China Pharmaceutical University, Nanjing, China |
POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS: |
08/2017 - 07/2018 Visiting Scholar in Dr. Siegfried Janz Lab, Pathology, University of Iowa, Iowa City, IA |
08/2018 - 07/2019 Project Appointment Student in Dr. Siegfried Janz Lab, Medicine, Hematology & Oncology, Medical College of Wisconsin, Milwaukee,, WI |
08/2019 - 08/2021 Postdoctoral Fellow in Dr. Siegfried Janz Lab, Medicine, Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI |
08/2021 - 12/2022 Postdoctoral Fellow in Dr. Fenghuang Zhan Lab, Hematology & Oncology, University of Arkansas for Medical Sciences, Little Rock, AR |
FACULTY APPOINTMENTS: |
12/2022 - 07/2024 Instructor, Internal Medicine, Myeloma Center, University of Arkansas for Medical Sciences (UAMS), 4301 W. Markham Street, Cancer Institute 12136, Little Rock, AR 72205 |
AWARDS AND HONORS: |
11/2016 Scholar-In-Training Award, American Association for Cancer Research, Shanghai, China |
09/2019 Young Investigator Award, International Myeloma Society, Boston, USA |
06/2020 Welman Pharmaceutical Annual Excellent PhD Thesis, Pharmaceutical University, China |
12/2022 2022 Abstract Achievement Award, American Society of Hematology (ASH), New Orleans, LA |
12/2023 2023 Abstract Achievement Award, American Society of Hematology (ASH), New Orleans, LA |
11/2024 Young Investigator Award Honoree, 24th Annual ECOG-ACRIN |
MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES: |
International Myeloma Society (IMS) |
American Society of Hematology (ASH) |
American Association for Cancer Research (AACR) |
EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS: |
Editorship |
Frontiers in Molecular Biosciences |
Journal Review |
Aging |
Molecular Medicine Reports |
Turkish Journal of Hematology |
Frontiers in Medicine |
Hematology |
Frontiers in Immunology |
Experimental and Therapeutic Medicine |
International Journal of Oncology |
Journal of Ethnopharmacology |
Oncology Letters |
Frontiers in Pharmacology |
RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS: | ||||||||||||||||||||||||||||||||||
|
INVITED LECTURES/WORKSHOPS/PRESENTATIONS: |
International |
A 12 Gene Signature Accurately Predicts Multiple Myeloma Progression from Monoclonal Gammopathy of Undetermined Significance, 2022 American Society of Hematology (ASH), New Orleans, LA, 12/2022 |
The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting CST6 Against Multiple Myeloma and Suppresses Osteolytic Lesions, 2023 American Society of Hematology (ASH), San Diego, CA, 12/2023 |
Dual-Target Inducible CAR-T Cell Therapy for Precise Management of Multiple Myeloma, 24th annual ECOG-ACRIN, Fort Lauderdale, FL, 11/2024 |
Local |
University of Iowa Myeloma Workshop, Iowa City, IA, 09/2018 |
18th MCW Cancer Center Scientific Retreat, Milwaukee, WI, 04/2019 |
Department of Medicine 6th Annual Research Retreat (MCW), Milwaukee, WI, 03/2020 |
2024 MCW Cancer Center Scientific Retreat, Milwaukee, WI, 11/2024 |
RESEARCH EXPERIENCE: |
Development of fourth-generation novel chimeric antigen receptor T-cell (CAR-T) immunotherapy. |
Development of novel therapeutic antibody drugs, including new antibodies, antibody-drug conjugates, and bispecific antibodies. |
Discovery of CAR-T cell exhaustion mechanisms through high-throughput screening of
CRISPR/Cas9 libraries. |
Research on the pathogenesis of multiple myeloma bone disease and the development of therapeutic drugs. |
Development of chimeric antigen receptor Natural Killer (CAR-NK) Cells. |
BIBLIOGRAPHY |
Refereed Journal Publications/Original Papers |
1. Sun F, Cheng Y, Chen JR, Wanchai V, Mery DE, Xu H, Gai D, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Tricot G, Shaughnessy JD Jr, Zhan F. BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions. J Clin Invest. 2024 Jan 02;134(1). PMCID: PMC10760955 |
2. Sun F, Cheng Y, Wanchai V, Guo W, Mery D, Xu H, Gai D, Siegel E, Bailey C, Ashby C, Al Hadidi S, Schinke C, Thanendrarajan S, Ma Y, Yi Q, Orlowski RZ, Zangari M, van Rhee F, Janz S, Bishop G, Tricot G, Shaughnessy JD Jr, Zhan F. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nat Commun. 2024 Jan 19;15(1):615. PMCID: PMC10798961 |
3. Sun F, Cheng Y, Ying J, Mery D, Al Hadidi S, Wanchai V, Siegel ER, Xu H, Gai D, Ashby TC, Bailey C, Chen JR, Schinke C, Thanendrarajan S, Zangari M, Janz S, Barlogie B, Van Rhee F, Tricot G, Shaughnessy JD Jr, Zhan F. A gene signature can predict risk of MGUS progressing to multiple myeloma. J Hematol Oncol. 2023 Jun 29;16(1):70. PMCID: PMC10308756 |
4. Sun F, Cheng Y, Riordan JD, Dupuy A, Dubois W, Pisano M, Dong J, Mock B, Zhan F, Hari P, Janz S. WDR26 and MTF2 are therapeutic targets in multiple myeloma. J Hematol Oncol. 2021 Dec 07;14(1):203. PMCID: PMC8650373 |
5. Sun F, Wang Y, Luo X, Ma Z, Xu Y, Zhang X, Lv T, Zhang Y, Wang M, Huang Z, Zhang J. Anti-CD24 Antibody-Nitric Oxide Conjugate Selectively and Potently Suppresses Hepatic Carcinoma. Cancer Res. 2019 Jul 01;79(13):3395-3405. |
6. Sun F, Cheng Y, Walsh SA, Acevedo MR, Jing X, Han SS, Pisano MD, Tomasson MH, Lichtenstein AK, Zhan F, Hari P, Janz S. Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma. Haematologica. 2020 Mar;105(3):e111-e115. PMCID: PMC7049347 |
7. Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Siegel ER, Xu H, Johnson S, Guo W, Bailey C, Ashby C, Bauer MA, Hadidi SA, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Tricot G, Shaughnessy JD Jr, Zhan F. Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages. Blood Cancer J. 2024 Nov 06;14(1):194. PMCID: PMC11541562 |
8. Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Guo W, Cao H, Zhu Y, Ashby C, Bauer MA, Nookaew I, Siegel ER, Ying J, Chen JR, Gai D, Peng B, Xu H, Bailey C, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, Chesi M, Bergsagel PL, van Rhee F, Janz S, Tricot G, Shaughnessy JD Jr, Zhan F. High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma. Cell Rep Med. 2023 Oct 17;4(10):101214. PMCID: PMC10591052 |
9. Cheng Y, Sun F, D'Souza A, Dhakal B, Pisano M, Chhabra S, Stolley M, Hari P, Janz S. Autonomic nervous system control of multiple myeloma. Blood Rev. 2021 Mar;46:100741. PMCID: PMC7876165 |
10. Pisano MD, Sun F, Cheng Y, Parashar D, Zhou V, Jing X, Sompallae R, Abrudan J, Zimmermann MT, Mathison A, Janz S, Pufall MA. IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma. Haematologica. 2023 Dec 01;108(12):3372-3383. PMCID: PMC10690922 |
11. Cheng Y, Sun F, Thornton K, Jing X, Dong J, Yun G, Pisano M, Zhan F, Kim SH, Katzenellenbogen JA, Katzenellenbogen BS, Hari P, Janz S. FOXM1 regulates glycolysis and energy production in multiple myeloma. Oncogene. 2022 Aug;41(32):3899-3911. PMCID: PMC9355869 |
12. Pan M, Wang F, Nan L, Yang S, Qi J, Xie J, Shao S, Zou H, Wang M, Sun F, Zhang J. αVEGFR2-MICA fusion antibodies enhance immunotherapy effect and synergize with PD-1 blockade. Cancer Immunol Immunother. 2023 Apr;72(4):969-984. PMCID: PMC10991987 |
13. Shi Y, Sun F, Cheng Y, Holmes B, Dhakal B, Gera JF, Janz S, Lichtenstein A. Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma. Mol Cancer Ther. 2022 Apr 01;21(4):502-510. PMCID: PMC8983490 |
14. Wang T, Sun F, Wang Y, Jiang J, Pan M, Yuan M, Zhang H, Du X, Hezam K, Song K, Wang M, Zhang J. NKG2D Immunoligand rG7S-MICA Enhances NK Cell-mediated Immunosurveillance in Colorectal Carcinoma. J Immunother. 2018 Apr;41(3):109-117. |
15. Sun F, Wang T, Jiang J, Wang Y, Ma Z, Li Z, Han Y, Pan M, Cai J, Wang M, Zhang J. Engineering a high-affinity humanized anti-CD24 antibody to target hepatocellular carcinoma by a novel CDR grafting design. Oncotarget. 2017 Aug 01;8(31):51238-51252. PMCID: PMC5584245 |
16. Fumou Sun, Yan Cheng, and Siegfried Janz. Genomic instability in multiple myeloma relevance for clinical outcome and efficacy of therapy. Blood&Genomics. 2019, 3(2):89-99. doi: 10.46701/APJBG.2019022019126. |
17. Fumou Sun, Yan Cheng, Siegfried Janz. Experimental model systems for preclinical research on Waldenström macroglobulinemia. Blood&Genomics. 2019, 3(1):9-18. doi: 10.46701/APJBG.2019012019114. |
18. Fumou Sun, Yan Cheng, Siegfried Janz. IgM memory and Waldenström macroglobulinemia’s cell of origin. Blood&Genomics. 2018, 2(4): 205-215. doi: 10.46701/APJBG.2018042018138 |
19. Yan Cheng, Fumou Sun, Xing Cui, et al. Genetic predisposition to multiple myeloma. Blood&Genomics, 2020, 4(1): 9-18. doi: 10.46701/BG2020012020103. |
20. Pisano M, Cheng Y, Sun F, Dhakal B, D'Souza A, Chhabra S, Knight JM, Rao S, Zhan F, Hari P, Janz S. Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma. Front Immunol. 2021;12:667054. PMCID: PMC8206561 |
21. Janz S, Zhan F, Sun F, Cheng Y, Pisano M, Yang Y, Goldschmidt H, Hari P. Germline Risk Contribution to Genomic Instability in Multiple Myeloma. Front Genet. 2019;10:424. PMCID: PMC6518313 |
22. Han Y, Sun F, Zhang X, Wang T, Jiang J, Cai J, Gao Q, Hezam K, Liu Y, Xie J, Wang M, Zhang J. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy. J Cancer Res Clin Oncol. 2019 May;145(5):1179-1190. |
23. Gai D, Chen JR, Stewart JP, Nookaew I, Habelhah H, Ashby C, Sun F, Cheng Y, Li C, Xu H, Peng B, Garg TK, Schinke C, Thanendrarajan S, Zangari M, Chen F, Barlogie B, van Rhee F, Tricot G, Shaughnessy JD Jr, Zhan F. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. J Clin Invest. 2022 Sep 15;132(18). PMCID: PMC9479617 |
24. Li JR, Arsang-Jang S, Cheng Y, Sun F, D'Souza A, Dhakal B, Hari P, Huang Q, Auer P, Li Y, Urrutia R, Zhan F, Shaughnessy JD Jr, Janz S, Dong J, Cheng C. Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing. Blood Cancer J. 2024 Mar 06;14(1):38. PMCID: PMC10915134 |
25. Sun X, Pisano M, Xu L, Sun F, Xu J, Zheng W, Liu X, Zhang Y, Sun R, Cui X. Baicalin regulates autophagy to interfere with small intestinal acute graft-versus-host disease. Sci Rep. 2022 Apr 21;12(1):6551. PMCID: PMC9023573 |
26. Zhang Y, Pisano M, Li N, Tan G, Sun F, Cheng Y, Zhang Y, Cui X. Exosomal circRNA as a novel potential therapeutic target for multiple myeloma-related peripheral neuropathy. Cell Signal. 2021 Feb;78:109872. |
27. Duan T, Xu Z, Sun F, Wang Y, Zhang J, Luo C, Wang M. HPA aptamer functionalized paclitaxel-loaded PLGA nanoparticles for enhanced anticancer therapy through targeted effects and microenvironment modulation. Biomed Pharmacother. 2019 Sep;117:109121. |
28. Hezam K, Jiang J, Sun F, Zhang X, Zhang J. Artemin promotes oncogenicity, metastasis and drug resistance in cancer cells. Rev Neurosci. 2018 Jan 26;29(1):93-98. |
29. Wang S, Zhou R, Sun F, Li R, Wang M, Wu M. The two novel DLL4-targeting antibody-drug conjugates MvM03 and MGD03 show potent anti-tumour activity in breast cancer xenograft models. Cancer Lett. 2017 Nov 28;409:125-136. |
30. Ma Z, He H, Sun F, Xu Y, Huang X, Ma Y, Zhao H, Wang Y, Wang M, Zhang J. Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo. J Cancer Res Clin Oncol. 2017 Oct;143(10):1929-1940. |
31. Li Z, Zhu Y, Li C, Trinh R, Ren X, Sun F, Wang Y, Shang P, Wang T, Wang M, Morrison SL, Zhang J. Anti-VEGFR2-interferon-α2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer. Oncoimmunology. 2017;6(3):e1290038. PMCID: PMC5384376 |
32. Xie W, Liu F, Wang Y, Ren X, Wang T, Chen Z, Tang M, Sun F, Li Z, Wang M, Zhang J. VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer. Oncotarget. 2016 Mar 29;7(13):16445-61. PMCID: PMC4941327 |
33. Wang T, Sun F, Xie W, Tang M, He H, Jia X, Tian X, Wang M, Zhang J. A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma. Cancer Lett. 2016 Mar 28;372(2):166-78. |
34. Gong J, Sun F, Li Y, Zhou X, Duan Z, Duan F, Zhao L, Chen H, Qi S, Shen J. Momordica charantia polysaccharides could protect against cerebral ischemia/reperfusion injury through inhibiting oxidative stress mediated c-Jun N-terminal kinase 3 signaling pathway. Neuropharmacology. 2015 Apr;91:123-34. |
35. Qi SH, Zhao H, Gong JJ, Sun FM, Yue J, Guan QH, Wang M. Neuroprotection of paclitaxel against cerebral ischemia/reperfusion-induced brain injury through JNK3 signaling pathway. J Recept Signal Transduct Res. 2011 Dec;31(6):402-7. |